Hubing Shi

Title: Hubing Shi - Innovator in Cancer Diagnostics and Therapy

Introduction

Hubing Shi is a prominent inventor based in Beijing, China. He has made significant contributions to the field of cancer diagnostics and therapy. His innovative work focuses on the role of Nucleolin in cancer treatment, providing new avenues for effective therapies.

Latest Patents

Hubing Shi holds a patent for "Nucleolin-mediated cancer diagnostics and therapy." This invention offers diagnostic kits designed to identify cancer patients who are more susceptible to therapies that utilize endostatin and other angiogenesis inhibitors. The discovery that Nucleolin serves as a specific receptor for Endostatin is pivotal. The diagnostic kits include antibody molecules against Nucleolin, as well as DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. Furthermore, the invention outlines methods for screening angiogenesis inhibitors that interact with Nucleolin and inhibit tumor angiogenesis.

Career Highlights

Throughout his career, Hubing Shi has worked with notable organizations, including Protogen Ltd. and Tsinghua University. His experience in these institutions has allowed him to advance his research and contribute to the scientific community.

Collaborations

Hubing Shi has collaborated with esteemed colleagues such as Yongzhang Luo and Zhuobing Zhang. These partnerships have enriched his research and expanded the impact of his work in cancer diagnostics.

Conclusion

Hubing Shi's innovative contributions to cancer diagnostics and therapy highlight the importance of research in improving patient outcomes. His work continues to inspire advancements in the medical field.